Abstract Library

#741 Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease

Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Nagourney R, Evans S, Woltering E, Gomez-Panzani E,

Keywords: combination therapy,

#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome

Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Brown P

Authors: Brown P, Jackson J, Frazier K, Turnage A, Clark E,

Keywords: carcinoid syndrome, TPH inhibitor, 5-HT, tryptophan hydroxylase, clinical trial, serotonin synthesis, serotonin synthesis inhibitor, LX1032, LX1031, Lexicon, IBS, irritable bowel syndrome, SSI,